About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Trp53tm3Glo
targeted mutation 3, Guillermina Lozano
MGI:3722177
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/? 		involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR MGI:3722604
cn2
 		Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/? 		involves: 129/Sv * C57BL/6 * FVB * ICR MGI:3722602


Genotype
MGI:3722604
cn1
Allelic
Composition		 Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/?
Genetic
Background		 involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (76 available)
Tg(KRT5-cre/PGR)1Der mutation (0 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (232 available)
Trp53tm3Glo mutation (0 available); any Trp53 mutation (232 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased incidence of tumors by chemical induction ( J:124222 )
• following treatment with RU486 and TPA, mice develop more tumors than in Krastm4Tyj Trp53tm1Brn/ Trp53tm1Brn Tg(KRT5-cre/PGR)1Der mice
increased carcinoma incidence ( J:124222 )
• following treatment with RU486 and TPA, conversion to malignant carcinoma is accelerated relative to in Krastm4Tyj Trp53tm1Brn/ Trp53tm1Brn Tg(KRT5-cre/PGR)1Der mice
increased spindle cell carcinoma incidence ( J:124222 )
• after RU486 and TPA treatment, 60% of tumors that develop are spindle cell carcinomas

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:124222 )
• following treatment with RU486 and TPA, mice develop more tumors than in Krastm4Tyj Trp53tm1Brn/ Trp53tm1Brn Tg(KRT5-cre/PGR)1Der mice




Genotype
MGI:3722602
cn2
Allelic
Composition		 Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/?
Genetic
Background		 involves: 129/Sv * C57BL/6 * FVB * ICR
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (76 available)
Tg(KRT5-cre/PGR)1Der mutation (0 available)
Trp53tm3Glo mutation (0 available); any Trp53 mutation (232 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased incidence of tumors by chemical induction ( J:124222 )
• after RU486 and TPA treatment, mice develop three-fold more tumors than Krastm4Tyj Trp53tm1Brn heterozygotes and Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes
increased metastatic potential ( J:124222 )
• after RU486 and TPA treatment, 60% of mice develop metastasis in the lungs and/or lymph nodes compared to no wild-type mice
abnormal tumor morphology ( J:124222 )
• after RU486 and TPA treatment, 42% of tumors exhibit aneuplody compared to 23% of Krastm4Tyj Trp53tm1Brn heterozygotes and 20% of Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes
• after RU486 and TPA treatment, tumors exhibit centrosome amplification in 3% to 5% of tumors cells
increased carcinoma incidence ( J:124222 )
• after RU486 and TPA treatment, carcinoma development is accelerated compared to in Krastm4Tyj Trp53tm1Brn heterozygotes and Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes
• after RU486 and TPA treatment, 90% of mice develop skin carcinomas compared to 30% of Krastm4Tyj Trp53tm1Brn heterozygotes and 5% of Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes

cellular
abnormal centrosome morphology ( J:124222 )
• after RU486 and TPA treatment, tumors exhibit centrosome amplification in 3% to 5% of tumors cells

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:124222 )
• after RU486 and TPA treatment, mice develop three-fold more tumors than Krastm4Tyj Trp53tm1Brn heterozygotes and Krastm4Tyj Tg(KRT5-cre/PGR)1Der heterozygotes




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
05/07/2024
MGI 6.23 		The Jackson Laboratory